* Lantus is an over the counter (OTC) item in Canada
* No prescription is required for any Lantus orders
* Buy Lantus Online Without A Prescription

Lantus is a recombinant human insulin analog that is a long-acting, parenteral blood-glucose-lowering agent. The activity of LANTUS results in a relatively constant concentration/time profile over 24 hours with no pronounced peak. This profile is what allows LANTUS to be dosed once a day as a patient's basal insulin. LANTUS provides a continuous level of insulin, similar to the slow, steady (basal) secretion of insulin provided by the normal pancreas. For optimal control, LANTUS may need to be prescribed in combination with short-acting insulins or oral hypoglycemic agents. Lantus is indicated for once-daily subcutaneous administration, at the same time each day, for the treatment of adult and pediatric patients (6 years and older) with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. “Prescription required for orders placed from the USA”. This item does not require a prescription in Canada. LANTUS MUST NOT BE DILUTED OR MIXED WITH ANY OTHER INSULIN OR SOLUTION. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Lantus is contraindicated in patients hypersensitive to insulin glargine or the excipients.

Lantus Side Effects:

Hypoglycemia (low blood sugar levels) is the most common adverse effect of insulin, including Lantus. As with all insulins, the timing of hypoglycemia may differ among various insulin formulations. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin type and/or regimen should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may need to be adjusted. Other adverse events commonly associated with Lantus include the following: lipodystrophy, skin reactions (such as injection-site reaction, pruritus, rash) and allergic reactions.

LANTUS may be administered at any time during the day. LANTUS should be administered once a day at the same time every day. LANTUS is not intended for intravenous administration. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycemia. The desired blood glucose levels as well as the doses and timing of antidiabetic medications must be determined individually. Blood glucose monitoring is recommended for all patients with diabetes. As with all insulins, injection sites within an injection area (abdomen, thigh or deltoid) must be rotated from one injection to the next. In clinical studies, there was no relevant difference in LANTUS absorption after abdominal, deltoid, or thigh subcutaneous administration. A detailed brochure on LANTUS and diabetes is available for distribution to your patients. Please contact your local Aventis Pharmaceuticals representative for more information. Lantus is indicated for once-daily subcutaneous administration, at the same time each day, for the treatment of adult and pediatric patients (6 years and older) with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. Initiation of LANTUS therapy- In a clinical study of insulin naïve patients with type 2 diabetes already treated with oral antidiabetic drugs, LANTUS® was started at an average dose of 10 IU once daily, and subsequently adjusted according to the patient's need to a total daily dosing range from 2 to 100 IU. Change to LANTUS- In clinical studies, when patients were transferred from once-daily NPH human insulin or Ultralente human insulin to once-daily LANTUS, the initial dose was usually not changed. However, when patients were transferred from twice-daily NPH human insulin to LANTUS once daily to reduce the risk of hypoglycemia, the initial dose (IU) was usually reduced by approximately 20% within the first weeks of treatment and then adjusted based on patient response. Pediatric use- LANTUS can be safely administered to pediatric patients 6 years of age or older. Based on the results of a study in pediatric patients, the dose recommendation for changeover to LANTUS is the same as described above for adults